EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2026 Interim Results at a glance

2026.08.05

H1 2026 Results Announcement: Regulatory Headwinds Drag Down, Revenue by 10.5% to HK$784.7 million and Profit by 32.2% to HK$110.7 million, Interim Dividend HK$0.05

2026.08.05

Essex Bio-Technology enters Strategic Collaboration Framework Agreement with Gunze Medical to further Commercial Access and to advance Research in Regenerative Medicine and Wound Care

2026.07.23

Date

Title

2021-03-19

Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD

2021-03-12

Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half

2021-02-24

Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease

2021-01-29

Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia

2020-11-23

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020

2020-10-15

Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases

2020-08-25

Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

2020-08-18

Essex Bio-Technology Reports First Half 2020 Financial Results

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT